Dysregulation in lipid metabolism is among the most prominent metabolic alterations in
cancer. Cancer cells harness lipid metabolism to obtain energy, components for biological …

Cancer is a major health issue worldwide, and the global burden of cancer is expected to
increase in the coming years. Whereas the limited success with current therapies has driven …

Resistance to therapeutic agents, either intrinsic or acquired, is currently a major problem in
the treatment of cancers and occurs in virtually every type of anti-cancer therapy. Therefore …

Background The proteasome inhibitor bortezomib (BTZ) is successfully applied in the
treatment of multiple myeloma, but its efficacy is restricted by the wide-spread occurrence of …

Despite significant advances in cancer diagnostics and therapeutics the majority of cancer
unfortunately remains incurable, which has led to continued research to better understand …

Proteasome inhibitor (PI) carfilzomib (CFZ) has activity superior to bortezomib (BTZ) and is
increasingly incorporated in multiple myeloma (MM) frontline therapy and relapsed settings …

Three proteasome inhibitors have garnered regulatory approvals in various multiple
myeloma settings; but drug resistance is an emerging challenge, prompting interest in …

In the past two decades, three highly pathogenic human coronaviruses severe acute
respiratory syndrome coronavirus (SARS‐CoV), Middle East respiratory syndrome …

The standard treatment of relapsed multiple myeloma has been either lenalidomide-
dexamethasone (RD) or bortezomib-dexamethasone (VD) but it is changing rapidly for 2 …

Simple Summary To this day, cancer remains a medical challenge despite the development
of cutting-edge diagnostic methods and therapeutics. Thus, there is a continual demand for …